Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Jost Hillenkamp
Compatibility of Recombinant Tissue Plasminogen Activator (rtPA) and Aflibercept or Ranibizumab Coapplied for Neovascular Age-Related Macular Degeneration With Submacular Haemorrhage
British Journal of Ophthalmology
Molecular Neuroscience
Ophthalmology
Sensory Systems
Cellular
The Long-Term Course of Functional and Anatomical Recovery After Macular Hole Surgery
Investigative Ophthalmology and Visual Science
Molecular Neuroscience
Ophthalmology
Sensory Systems
Cellular
Related publications
Effects of Intravitreal Gas With or Without Tissue Plasminogen Activator on Submacular Haemorrhage in Age-Related Macular Degeneration
Eye
Medicine
Arts
Sensory Systems
Ophthalmology
Humanities
Aflibercept for Neovascular Age-Related Macular Degeneration
Cochrane Database of Systematic Reviews
Ranibizumab Versus Verteporfin for Neovascular Age-Related Macular Degeneration
New England Journal of Medicine
Medicine
Worsening Anatomic Outcomes Following Aflibercept for Neovascular Age-Related Macular Degeneration in Eyes Previously Well Controlled With Ranibizumab [Corrigendum]
Clinical Ophthalmology
Ophthalmology
Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data From an Observational Study
Ophthalmology
Ophthalmology
Ranibizumab Monotherapy in Neovascular Age-Related Macular Degeneration With Pigment Epithelial Detachment
Journal of Clinical & Experimental Ophthalmology
Baseline Predictors for One-Year Visual Outcomes With Ranibizumab or Bevacizumab for Neovascular Age-Related Macular Degeneration
Ophthalmology
Ophthalmology
Macular Functional Changes in Patients With Neovascular Age-Related Macular Degeneration Receiving Ranibizumab Therapy (Lucentis)
BMC Geriatrics
Gerontology
Geriatrics
Ranibizumab in Neovascular Age-Related Macular Degeneration: A 5-Year Follow-Up
Clinical Ophthalmology
Ophthalmology